Shuttle Pharmaceuticals Holdings, Inc. (SHPH) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Gaithersburg, MD, 미국. 현재 CEO는 Christopher Robert Cooper.
SHPH 을(를) 보유 IPO 날짜 2022-08-31, 9 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $990.36K.
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
